🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 1 día
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/03/2021 52,56 52,99 49,33 49,53 -4,80% 6,96% 608.700
23/03/2021 55,21 55,25 51,58 52,03 -8,75% 6,65% 1.437.500
22/03/2021 56,10 57,82 55,78 57,02 +1,50% 3,63% 362.900
19/03/2021 55,69 57,19 55,36 56,18 +1,21% 3,29% 1.123.700
18/03/2021 55,28 58,58 55,15 55,51 -0,43% 6,20% 381.100
17/03/2021 57,64 57,64 55,10 55,75 -3,38% 4,42% 596.900
16/03/2021 58,00 59,48 56,35 57,70 -0,64% 5,40% 582.000
15/03/2021 58,05 58,88 57,53 58,07 -0,65% 2,33% 229.600
12/03/2021 56,28 59,19 55,82 58,45 +2,13% 6,00% 429.400
11/03/2021 57,53 58,44 56,82 57,23 +1,20% 2,82% 401.200
10/03/2021 59,58 60,14 55,77 56,55 -4,41% 7,33% 638.300
09/03/2021 59,60 60,61 58,64 59,16 +1,28% 3,31% 363.800
08/03/2021 60,48 60,57 58,30 58,41 -2,88% 3,75% 444.500
05/03/2021 58,61 60,24 56,37 60,14 +3,92% 6,60% 926.800
04/03/2021 56,89 58,71 55,67 57,87 +1,53% 5,34% 920.300
03/03/2021 57,42 58,02 56,36 57,00 -0,56% 2,88% 398.900
02/03/2021 58,18 58,75 57,09 57,32 -1,44% 2,85% 407.100
01/03/2021 57,86 58,44 56,91 58,16 +1,86% 2,64% 635.400
26/02/2021 54,41 57,68 54,00 57,10 +3,46% 6,76% 972.400
25/02/2021 57,64 58,53 55,09 55,19 -4,23% 5,97% 515.500
24/02/2021 57,06 58,99 56,27 57,63 +0,59% 4,77% 588.700
23/02/2021 56,85 58,73 56,00 57,29 -0,19% 4,79% 541.000
22/02/2021 57,35 58,95 57,00 57,40 -1,17% 3,40% 526.100
19/02/2021 59,11 60,43 57,90 58,08 -1,29% 4,28% 534.700
18/02/2021 58,56 59,91 58,01 58,84 -1,08% 3,24% 378.300
17/02/2021 60,95 60,95 58,93 59,48 -1,54% 3,31% 536.500
16/02/2021 61,43 61,66 59,98 60,41 -1,66% 2,73% 500.500
12/02/2021 61,81 62,89 61,38 61,43 -2,92% 2,44% 779.400
11/02/2021 64,47 64,63 63,07 63,28 -0,73% 2,42% 599.400
10/02/2021 64,58 65,49 63,35 63,74 -0,02% 3,31% 365.500